License revenues and EBITDA stabilizing
Second quarter 2024 (April - June)- Total revenue amounted to
SEK 60.9 (51.2) million, an increase of SEK 9.7 million corresponding to 18.9%. -
Net sales amounted to
SEK 57.4 (44.2) million, an increase of SEK 13.2 million corresponding to 29.8%. Adjusted for currency effects of SEK 0.2 million , net sales increased by 30.1%. -
Operating loss amounted to
SEK 10.8 (67.8) million.* -
EBITDA amounted to
SEK 1.2 (-55.7) million.* -
Net loss for the period amounted to
SEK 14.3 (64.5) million.* -
Loss per share, before and after dilution, amounted to
SEK 0.41 (1.84). -
Cash flow from operating activities amounted to
SEK 16.8 (-19.7) million corresponding to SEK 0.48
(-0.56) per share.
First half-year 2024 (January - June)- Total revenue amounted to
SEK 119.7 (112.4) million, an increase of SEK 7.3 million corresponding to 6.5%. -
Net sales amounted to
SEK 111.3 (99.8) million, an increase of SEK 11.4 million corresponding to 11.5%. Adjusted for currency effects of SEK 0.5 million , net sales increased by 11.0%. -
Operating loss amounted to
SEK 23.7 (86.5) million.* -
EBITDA amounted to
SEK -0.3 (-62.3) million.* -
Net loss for the period amounted to
SEK 24.2 (86.6) million.* -
Loss per share, before and after dilution, amounted to
SEK 0.69 (2.47). -
Cash flow from operating activities amounted to
SEK -2.2 (-27.4) million corresponding to SEK -0.06
(-0.78) per share.
(-0.56) per share.
- Total revenue amounted to
SEK 119.7 (112.4) million, an increase ofSEK 7.3 million corresponding to 6.5%. -
Net sales amounted to
SEK 111.3 (99.8) million, an increase ofSEK 11.4 million corresponding to 11.5%. Adjusted for currency effects ofSEK 0.5 million , net sales increased by 11.0%. -
Operating loss amounted to
SEK 23.7 (86.5) million.* -
EBITDA amounted to
SEK -0.3 (-62.3) million.* -
Net loss for the period amounted to
SEK 24.2 (86.6) million.* -
Loss per share, before and after dilution, amounted to
SEK 0.69 (2.47). -
Cash flow from operating activities amounted to
SEK -2.2 (-27.4) million corresponding toSEK -0.06
(-0.78) per share.
* The difference is mainly pertained to the
CEO statement
Total revenue for Q2 amounted to
Embarking on the path to profitability
Revenues from the license business were stable in the second quarter and amounted to
The Wound Management portfolio delivered revenues of
Q2 2024 total operating expenses (OPEX) amounted to
Total cash flow for the quarter amounted to
Bactiguard coated medical devices expand into new markets
The market activities with
The collaboration with BD, including the transition process of
In May, we featured our wound healing product line Hydrocyn aqua in
Outlook - further strengthen knowledge and specialist organization
In July, we strengthened the organization with
Looking ahead, we keep our focus on enhancing the business with our current license partners, and simultaneously, increasing interactions and early-stage testing of our infection prevention technology with leading
This information is information that
For further information, please contact:
To participate in the audiocast, please use this link:
https://ir.bactiguard.com/report/q2-2024/
To participate only by conference call, please register on the link above.
Questions can be asked either in writing via the audiocast or orally if you attend the conference call.
About
Read more about
Follow
https://news.cision.com/bactiguard-holding-ab--publ-/r/bactiguard-holding-ab-s-interim-report-second-quarter-2024,c4015335
https://mb.cision.com/Main/9686/4015335/2916992.pdf
https://mb.cision.com/Public/9686/4015335/bf64ffda31e0b8f7.pdf
(c) 2024 Cision. All rights reserved., source